The role played by traditional Chinese medicine in preventing and treating COVID-19 in China

Li, Qingwei; Wang, Han; Li, Xiuyang; Zheng, Yujiao; Wang, Yu; Zhang, Pei; Ding, Qiyou; Lin, Jiaran; Táng, Shuāng; Zhao, Yi-Kun; Zhao, Linhua; Tong, Xiaolin

doi:10.1007/s11684-020-0801-x

Cited by 64 publications

(75 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of a meta-analysis of 16 papers, including 1335 cases of sepsis in a Chinese population, showed that, compared with ulinastatin alone, the combination of Xuebijing with ulinastatin led to a shorter mechanical ventilation time, shorter ICU stay, improved 28-day survival rate, reduced incidence of MODS and mortality, decreased procalcitonin concentration, ameliorated acute physiology and chronic health evaluation (APACHE) II score, and reduced levels of TNF-α and IL-6 ( 94 ). Xuebijing also exhibited antithrombotic activity, which could prevent vascular embolism caused by COVID-19 ( 91 ). Xuebijing has been recommended for the treatment of severe COVID-19 in China ( 51 ).…”

Section: Immunotherapy Strategies For Patients With Critically Ill Comentioning

confidence: 99%

Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art

2020

View full text Add to dashboard Cite

Section: Immunotherapy Strategies For Patients With Critically Ill Comentioning

confidence: 99%

Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art

2020

View full text Add to dashboard Cite

“…Symptomatic support therapy and comprehensive interventions are mainly used in clinical practice (Wu et al, 2020b). Since the outbreak of COVID-19 (Wu et al, 2020b), TCM has been able to get involved in the whole process of treatment and achieved remarkable results (Li et al, 2020). TCM integrates its treatment principles (syndrome differentiation and threeconcerned therapy of "individual concerned therapy, environment concerned therapy, climate concerned therapy") (Wu et al, 2020a) with the different stages of COVID-19.…”

Section: Resultsmentioning

confidence: 99%

A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China

Zhang

Shi

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: This research aims to analyze the application regularity of Chinese patent medicine during the COVID-19 epidemic by collecting the names of the top three Chinese patent medicines used by 24 hospitals in 14 provinces of China in four time periods (January 20–22, February 16–18, March 01–03, April 01–03, 2020), and explore its contribution to combating the disease.Methods: 1) We built a database of the top three Chinese patent medicines used by 24 hospitals. 2) The frequency and efficacy distribution of Chinese patent medicine were analyzed with risk areas, regions, and hospitals of different properties as three factors. 3) Finally, we analyzed the differences in the use of heat-clearing and non-heat-clearing medicines among the three factors (χ2 test) and the correlation between the Chinese patent medicine and COVID-19 epidemic (correlation analysis) with SPSS 23.0 statistical software.Results: 1) The heat-clearing medicine was the main use category nationwide during January 20–22, 2020. Meanwhile, there was a significant difference in the utilization rate of heat-clearing and non-heat-clearing medicine in different risk areas (p < 0.01). 2) The variety of Chinese patent medicine was increased nationwide during February 16–18, 2020, mainly including tonics, blood-activating and resolving-stasis, and heat-clearing medicines. Meanwhile, there was a significant difference in the utilization rate of heat-clearing and non-heat-clearing medicine in the southern and northern regions (p < 0.05). 3) Tonics, and blood-activating and resolving-stasis medicines became the primary use categories nationwide during March 01–03, 2020. 4) The tonics class, and blood-activating and resolving-stasis medicine were still the primary categories nationwide during April 01–03, 2020. Meanwhile, there was a significant difference in the utilization rate of heat-clearing and non-heat-clearing medicine in different risk areas (p < 0.01).Conclusion: Chinese patent medicine has a certain degree of participation in fighting against the COVID-19. The efficacy distribution is related to the risk area, region, and hospital of different properties, among which the risk area is the main influencing factor. It is hoped that future research can further collect the application amount of Chinese patent medicine used in hospitals all over the country, so as to perfectly reflect the relationship between Chinese patent medicine and the epidemic situation.

show abstract

“…Besides, based on the composition of the MXSGT, the Qing Fei Pai Du Decoction (QFPDD) and Lianhua Qingwen Capsules (LHQWC) were manufactured and issued by the National Health Commission and have been widely used in China to treat the COVID-19 patients. Data has suggested significant positive clinical outcomes [18] , [19] , [20] , [21] .…”

Section: Resultsmentioning

confidence: 99%

Exploring the potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis

Sun

Jiang

Liu

2020

European Journal of Integrative Medicine

View full text Add to dashboard Cite

Introduction Historically traditional Chinese medicine (TCM) has been used as treatment during epidemics. During the recent COVID-19 pandemic patients evidence suggests that the use of TCM has provided health benefits and has been successfully used to control the spread of the disease in China. The aim of this study was to systematically explore the TCM formulae which have been used for the prevention and treatment of pneumonia or ‘pestilence’ to investigate their compatibility with the Chinese materia medica (CMM) and understand their potential mechanisms in the treatment of COVID-19. Methods Frequency analysis was performed to identify high-frequency CMM and CMM groups. Association rules analysis was applied to investigate the compatibility law of CMMs and generate the commonly used CMM groups. Results A total of 173 prescriptions were collected. The frequency analysis showed that seven out of ten high-frequency CMMs overlapped with Lianhua Qingwen Capsules (LHQWC), and five high-frequency pair-CMMs and four triple-CMMs were included in LHQWC, respectively. Then three groups of CMM were generated from association rules analysis, one of which is Ma Xing Shi Gan Decoction (MXSGD). The results of the protein-protein interaction network and enrichment analysis showed that the potential therapeutic mechanisms of the generated prescriptions were involved in the anti-inflammatory, anti-viral, and neuroprotective effects. Conclusion This study showed the importance of systematic research on TCM prescriptions and provided candidate CMM groups that have the potential to treat COVID-19. In vitro and in vivo experiments should be conducted to validate these network pharmacology results, which can provide more information for the development of potential antiviral drugs from TCM prescriptions. The combination of TCM treatment and modern medical approaches will benefit patients with COVID-19 and help to overcome the current epidemic.

show abstract

The role played by traditional Chinese medicine in preventing and treating COVID-19 in China

Cited by 64 publications

References 8 publications

Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art

Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art

A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China

Exploring the potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis

Contact Info

Product

Resources

About